Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib
Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Economic Evaluation of Plerixafor for Stem Cell Mobilization
Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.